Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 17;21(1):157.
doi: 10.1186/s12888-021-03116-2.

Role of insulin-like growth factor 1, sex and corticosteroid hormones in male major depressive disorder

Affiliations

Role of insulin-like growth factor 1, sex and corticosteroid hormones in male major depressive disorder

Hiroshi Arinami et al. BMC Psychiatry. .

Abstract

Background: Hormones of the hypothalamic-pituitary-gonadal (HPG), hypothalamic-pituitary-adrenal (HPA), and hypothalamic-pituitary-somatotropic (HPS) axes are potentially involved in major depressive disorder (MDD), but these hormones have not been simultaneously investigated in male patients with MDD. We investigated the association between male MDD symptoms and estradiol, testosterone, cortisol, dehydroepiandrosterone sulfate (DHEAS), and insulin-like growth factor 1 (IGF1).

Methods: Serum estradiol, testosterone, cortisol, DHEAS, and IGF1 levels were measured in 54 male patients with MDD and 37 male controls and were compared with clinical factors. We investigated the associations between hormone levels and Hamilton Depression Rating Scale (HAM-D) scores. The correlations among hormones were also investigated.

Results: Patients had significantly lower estradiol levels than controls (22.4 ± 8.4 pg/mL vs. 26.1 ± 8.5 pg/mL, P = 0.040). Serum estradiol levels were negatively correlated with HAM-D scores (P = 0.000094) and positively correlated with Global Assessment of Functioning scores (P = 0.000299). IGF1 levels and the cortisol:DHEAS ratio were higher in patients than in controls (IGF1: 171.5 ± 61.8 ng/mL vs. 144.1 ± 39.2 ng/mL, P = 0.011; cortisol:DHEAS ratio: 0.07 ± 0.05 vs. 0.04 ± 0.02, P = 0.001). DHEAS levels were lower in patients than in controls (227.9 ± 108.4 μg/dL vs. 307.4 ± 131.2 μg/dL, P = 0.002). IGF1, cortisol:DHEAS ratio, and DHEAS were not significantly correlated with HAM-D scores. Cortisol and testosterone levels were not significantly different between patients and controls. Serum estradiol levels were positively correlated with DHEAS levels (P = 0.00062) in patients, but were not significantly correlated with DHEAS levels in controls.

Conclusion: Estradiol may affect the pathogenesis and severity of patients with MDD in men, and other hormones, such as those in the HPA and HPS axes, may also be involved in male MDD. Additionally, a correlation between estradiol and DHEAS may affect the pathology of MDD in men.

Keywords: Cortisol; DHEAS; Estradiol; IGF1; Testosterone.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Scatterplot of serum estradiol versus HAM-D (a) and serum estradiol versus GAF scores (b) in male patients with MDD. Serum estradiol showed significant negative correlation with HAM-D scores (P = 0.0000940) (a) and significant positive correlation with GAF scores (P = 0.000299) (b)

References

    1. McHenry J, Carrier N, Hull E, Kabbaj M. Sex differences in anxiety and depression: role of testosterone. Front Neuroendocrinol. 2014;35(1):42–57. doi: 10.1016/j.yfrne.2013.09.001. - DOI - PMC - PubMed
    1. Fischer S, Ehlert U, Amiel CR. Hormones of the hypothalamic-pituitary-gonadal (HPG) axis in male depressive disorders-a systematic review and meta-analysis. Front Neuroendocrinol. 2019. 10.1016/j.yfrne.2019.100792. - PubMed
    1. Komesaroff P, Fullerton M, Esler MD, Jennings G, Sudhir K. Oestrogen supplementation attenuates responses to psychological stress in elderly men rendered hypogonadal after treatment for prostate cancer. Clin Endocrinol (Oxf) 2002;56(6):745–753. doi: 10.1046/j.1365-2265.2002.01542.x. - DOI - PubMed
    1. Fisher AD, Castellini G, Bandini E, Casale H, Fanni E, Benni L, et al. Cross-sex hormonal treatment and body uneasiness in individuals with gender dysphoria. J Sex Med. 2014;11(3):709–719. doi: 10.1111/jsm.12413. - DOI - PubMed
    1. Colizzi M, Costa R, Todarello O. Transsexual patients' psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: results from a longitudinal study. Psychoneuroendocrinology. 2014;39:65–73. doi: 10.1016/j.psyneuen.2013.09.029. - DOI - PubMed

Publication types

LinkOut - more resources